# Dhansa Labs Limited

Formerly known as Ambey Laboratories Limited
CIN: L74899DL1985PLC020490
REG. OFFICE: GROUND FLOOR, PROPERTY NO.555 TARLA MOHALLA,
GHITORNI, SOUTH WEST DELHI-110030 INDIA
Contact: 9899664458, Email: accountho@ambeylab.com
www. dhansalabs.com

**Date: 14th November, 2026**

To,

**The Manager — Listing Department**
**National Stock Exchange of India Limited**
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (East),
Mumbai - 400 051, Maharashtra, India

**Symbol: DHANSA**
**ISIN : INE0M3I01029**

**Sub: Outcome of the Board Meeting**

**Ref: Regulation 30 (read with Part A of Schedule III) and Regulation 33 and other applicable Regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

**Dear Sir/Madam,**

Pursuant to Regulations 30, 33 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we wish to inform you that the Board of Directors of Dhansa Labs Limited (the "Company"), at its meeting held today, i.e., November 14, 2026, has, inter alia, considered and approved the following, based on the recommendation of the Audit Committee:

1. The Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2026, along with the Limited Review Report issued by the Statutory Auditors thereon. The Financial Results are annexed hereto as Annexure A.

Further, an extract of the aforementioned Unaudited Financial Results (Standalone and Consolidated) shall be published in newspapers in accordance with the provisions of the SEBI LODR Regulations.

The aforesaid Unaudited Financial Results (Standalone and Consolidated) will be uploaded on the Company's website at https://dhansalabs.com/ and will also be available on the website of NSE at https://www.nseindia.com/ for the benefit of shareholders and investors.

2. The appointment of M/s. K.K. Baranwal & Associates as the Internal Auditor of the Company, with effect from November 14, 2026. The details required under Regulation 30 of the SEBI Listing Regulations read with the SEBI Master Circular are enclosed as Annexure B.

The Meeting of the board of directors of the Company commenced at 18:30 PM (IST) and concluded at 21:45 PM (IST).

# Dhansa Labs Limited

Formerly known as Ambey Laboratories Limited
CIN: L74899DL1985PLC020490
REG. OFFICE: GROUND FLOOR, PROPERTY NO.555 TARLA MOHALLA,
GHITORNI, SOUTH WEST DELHI-110030 INDIA
Contact: 9899664458, Email: accountho@ambeylab.com
www. dhansalabs.com

Further, in continuation to our earlier intimation dated September 28, 2026, regarding closure of trading window, we wish to inform you that the trading window for dealing in the securities of the Company has been closed from October 01, 2026, and shall re-open after 48 hours from the declaration of the financial results of the Company.

This outcome of Board Meeting will also be made available on the website of the Company at https://dhansalabs.com/.

We request you to take the above information on records.

Thanking You,

Yours Faithfully,
**For Dhansa Labs Limited**

Himanshu Kukreja

Digitally signed by Himanshu Kukreja
Date: 2026.11.14 22:38:04 +05'30'

**Himanshu Kukreja**
**Company Secretary & Compliance Officer**
**Membership No: A64853**

*Enclosed:*
*Annexure-A*
*Annexure-B*

# Dhansa Labs Limited

Formerly known as Ambey Laboratories Limited
CIN: L74899DL1985PLC020490
REG. OFFICE: GROUND FLOOR, PROPERTY NO.555 TARLA MOHALLA,
GHITORNI, SOUTH WEST DELHI-110030 INDIA
Contact: 9899664458, Email: accountho@ambeylab.com
www. dhansalabs.com


**ANNEXURE – B**

*Details as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated the 30th January, 2026*

| Sr. No. | Details of Events that need to be provided | Appointment of M/s. K.K. Baranwal & Associates |
|---|---|---|
| a) | **Reason for change viz. appointment, / reappointment, resignation, removal, death or otherwise** | Appointment as Internal Auditor of the Company, in view of the growing scale and complexity of the Company's operations, including its subsidiaries, and to further strengthen the Company's internal control, risk management and governance framework by engaging a firm with specialised expertise in internal audit. |
| b) | **Date of appointment/reappointment/ cessation (as applicable) & term of Appointment/ reappointment;** | Date of appointment – November 14, 2026 |
| c) | **Brief profile (in case of appointment);** | K K BARANWAL & ASSOCIATES (KKB) is a 15 years old CA Firm started by CA Krishna Kumar Baranwal in the year 2011.<br><br>KKB has professional experience of more than one decade with committed team of professionals, Audit Assistants and Article Assistants.<br><br>KKB is a premier Accounting Firm offering professional services in areas of Direct and Indirect Taxation, Audit & Assurance, Corporate Law Services, Finance and Accounts Outsourcing Services and Business Start-up and Development services. |
| d) | **Disclosure of relationships between directors (in case of appointment of a director).** | Not Applicable |

**KAPISH JAIN & ASSOCIATES**
Chartered Accountants

117, 1st Floor, New Delhi House,
27, Barakhamba Road,
New Delhi – 110001
Tel: +91-11-40508780
Mob: +91 9711611551
Email: info@cakja.com

**Independent auditor's review report on standalone unaudited financial results for the Quarter and Half Year Ended 30 September 2026 of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

**Review Report to**
**The Board of Directors**
**Dhansa Labs Limited**
(Formerly known as Ambey Laboratories Limited)

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results ("Statement") of **Dhansa Labs Limited** (Formerly known as Ambey Laboratories Limited) ("the Company") for the quarter and half year ended 30 September 2026. The Company is submitting the Statement pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the relevant circulars issued by SEBI from time to time.

2. This statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the generally accepted accounting principles in India ("GAAP") and in compliance with the applicable Accounting Standard as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statements are free of material misstatements. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the generally accepted accounting principles in India ("GAAP") and in compliance with the applicable Accounting Standard as specified under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation, read with Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.



5. During the year ended 31 March 2026, the company allotted 1,08,69,565 convertible equity warrants on preferential basis at an issue price of Rs. 46/- per warrant, aggregating to Rs. 4,999.99 lakhs, in accordance with Section 42 and Section 62(1)(c) of the Companies Act, 2013 and applicable provisions of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. Against the said warrants, the company has received Rs. 2,161.54 lakhs up to 30 September 2026 towards warrant subscription/part consideration.

   The money received against these warrants has been utilized for the purposes detailed in the table below.

*(Rs. in lacs unless otherwise stated)*

| Object of issue | Total issue size | Amount received till September 30, 2026 | Amount utilized till September 30, 2026 | Amount unutilized as on September 30, 2026 | Deviation (if any) |
|---|---|---|---|---|---|
| The funds were utilized towards general corporate purposes, advances for plant and machinery, supporting ongoing capital expenditure; and land-related advances. | 4999.99 | 2161.54 | 2161.54 | - | N/A |

For **KAPISH JAIN & ASSOCIATES**
Chartered Accountants
Firm Registration No. 022743N

**CA Kapish Jain**
Partner
M. No.: 514162
UDIN: 26514162WFNCXL4610
Place: New Delhi
Date: 14 November 2026

**DHANSA LABS LIMITED**

**(Formerly known as Ambey Laboratories Limited)**

Regd. Office : Ground Floor,Property No.555 Tarla Mohalla,Ghitorni, South West Delhi, Delhi, India, 110030

Corp. Office : B18/9, Dlf Phase -1 Sector 26A, Gurugram-122002, Gurugram, Haryana, India, 122002

CIN: L74899DL1985PLC020490, Email:cs@ambeylab.com

**STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS**

**FOR THE QUARTER , HALF YEAR ENDED 30 SEPTEMBER 2026**

*(All amounts in Rs. lacs, unless stated otherwise)*

| Sl. No | Particulars | Quarter ended | | | Half Year ended | | | Year ended |
|---|---|---|---|---|---|---|---|---|
| | | 30.09.2026 (Unaudited) | 30.06.2026 (Unaudited) | 30.09.2025 (Unaudited) | 30.09.2026 (Unaudited) | 31.03.2026 (Unaudited) | 30.09.2025 (Unaudited) | 31.03.2026 (Audited) |
| 1 | **Income** | | | | | | | |
| | a) Revenue from operations | 4,001.34 | 3,056.29 | 3,988.63 | 7,057.62 | 7,336.14 | 6,817.59 | 14,153.72 |
| | b) Other income | 2.90 | 63.34 | 11.32 | 66.24 | 137.94 | 13.37 | 151.30 |
| | **Total income** | **4,004.24** | **3,119.63** | **3,999.95** | **7,123.86** | **7,474.08** | **6,830.96** | **14,305.02** |
| 2 | **Expenses** | | | | | | | |
| | a) Cost of material consumed | 3,377.77 | 2,891.70 | 3,010.65 | 6,269.47 | 6,803.79 | 6,176.51 | 12,980.30 |
| | b) Changes in inventories of work-in-progress, finished goods | 122.26 | (194.07) | 506.07 | (71.81) | (113.23) | (226.46) | (339.69) |
| | c) Employee benefits expense | 41.15 | 30.32 | 46.63 | 71.47 | 38.77 | 77.01 | 115.78 |
| | d) Finance costs | 81.15 | 70.61 | 92.44 | 151.76 | 70.28 | 192.11 | 262.39 |
| | e) Depreciation and amortisation expense | 44.89 | 44.15 | 55.36 | 89.04 | 109.69 | 110.09 | 219.78 |
| | f) Other expenses | 123.83 | 62.97 | 122.19 | 186.79 | 104.71 | 201.13 | 305.83 |
| | **Total expenses** | **3,791.05** | **2,905.68** | **3,833.34** | **6,696.72** | **7,014.01** | **6,530.39** | **13,544.39** |
| 3 | **Profit/(loss) before exceptional item & tax (1-2)** | **213.19** | **213.95** | **166.64** | **427.14** | **460.06** | **300.57** | **760.63** |
| 4 | Exceptional Items | - | - | - | - | - | - | - |
| 5 | **Profit/(loss) before tax (3-4)** | **213.19** | **213.95** | **166.64** | **427.14** | **460.06** | **300.57** | **760.63** |
| 6 | Tax expense | | | | | | | |
| | -Current tax | 29.19 | 59.16 | 34.16 | 88.35 | 70.44 | 56.52 | 192.11 |
| | -Deferred tax charge/ (benefit) | 10.94 | 20.92 | 24.22 | 31.86 | (43.14) | 38.40 | (4.74) |
| | -MAT credit entitlement | - | - | (34.16) | - | 121.67 | (56.52) | - |
| | **Tax expense** | **40.14** | **80.08** | **24.22** | **120.21** | **148.97** | **38.40** | **187.37** |
| 7 | **Net Profit/(Loss) after tax (5-6)** | **173.06** | **133.87** | **142.42** | **306.93** | **311.09** | **262.17** | **573.26** |
| 8 | **Paid-up Equity Share Captial (Face value of Rs.10/- each)** | 2,690.33 | 2,690.33 | 2,494.68 | 2,690.33 | 2,494.68 | 2,494.68 | 2,494.68 |
| 9 | Reserves (excluding revaluation reserve) | | | | | | | 4,663.60 |
| 10 | **Earnings per equity share** | | | | | | | |
| | **[Nominal value per share Rs. 10] (not annualised, except year end)** | | | | | | | |
| | Basic earnings per share (in ₹ ) | 0.65 | 0.51 | 0.57 | 1.16 | 1.25 | 1.05 | 2.30 |
| | Diluted earnings per share (in ₹ ) | 0.65 | 0.51 | 0.57 | 1.16 | 1.25 | 1.05 | 2.30 |

**Notes:-**

**1** The above Financial Results were reviewed by the Audit Committee and were thereafter approved by the Board of Directors at their meeting held on 14 November, 2026.

**2** The above results have been prepared in accordance with the recognition and measurement principles of Accounting Standard ("AS"), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

**3** The Company primarily engaged in the business of manufacturing and distribution of agro and home hygiene products. Hence, the Company has a single reportable segment as per the Accounting Standard - 17.

**For and on behalf of the Board of Directors of**
Dhansa Labs Limited
(Formely known as Ambey laboratories limited)

ARCHIT GUPTA
Digitally signed by ARCHIT GUPTA
Date: 2026.11.14 21:35:03 +05'30'

**Archit Gupta**
Whole Time Director
DIN: 00378409

Date: 14 November 2026
Place: Gurugram

| 4 | | STANDALONE STATEMENT OF ASSETS & LIABILITIES | *(All amounts in Rs. lacs, unless stated otherwise)* | |
|---|---|---|---|---|
| | | **Particulars** | **Standalone** | |
| | | | **As at 30.09.2026** | **As at 31.03.2026** |
| | | **EQUITY AND LIABILITIES** | | |
| | 1 | **Shareholders' funds** | | |
| | | a) Share capital | 2,690.33 | 2,494.68 |
| | | b) Reserves and surplus | 6,724.87 | 5,713.60 |
| | | c) Money Received Against share warrant | 1,261.50 | 1,697.53 |
| | | **Total Equity** | **10,676.70** | **9,905.81** |
| | 2 | **Share Application Money Pending Allotment** | - | - |
| | 3 | **Liabilities** | | |
| | | **Non-current liabilities** | | |
| | | a) Long-Term Borrowings | 2,343.67 | 1,882.91 |
| | | b) Deferred tax liabilities | - | - |
| | | c) Other long-term liabilities | - | - |
| | | d) Long-term provisions | 41.90 | 41.88 |
| | | **Total non-current liabilities** | **2,385.57** | **1,924.79** |
| | | **Current liabilities** | | |
| | | a) Short-Term Borrowings | 1,958.93 | 2,074.55 |
| | | b) Trade payables | | |
| | | (i) Total outstanding dues of micro enterprises and | 122.11 | 68.26 |
| | | (ii) Total outstanding dues of creditors other than micro enterprises and small enterprises | 2,200.77 | 559.43 |
| | | c) Other current liabillities | 7,947.72 | 273.29 |
| | | d) Short-term provisions | 185.32 | 123.53 |
| | | **Total current liabilities** | **12,414.85** | **3,099.06** |
| | | **Total equity and liabilities** | **25,477.12** | **14,929.66** |
| | | **Assets** | | |
| | 1 | **Non-current assets** | | |
| | | a) Property, plant and equipment | | |
| | | (i) Property ,pant and equipment | 1,975.22 | 2,054.45 |
| | | (i) Intangible assets | 39.17 | 44.36 |
| | | (iii) Capital work-in-progress | 2,987.14 | 2,203.83 |
| | | b) Non-current investments | 930.00 | 10.00 |
| | | c) Deferred tax assets (Net) | 114.94 | 146.80 |
| | | d) Long-term loans and advances | 3,396.41 | 568.09 |
| | | e) Other non-current assets | - | - |
| | | **Total non-current assets** | **9,442.88** | **5,027.54** |
| | 2 | **Current assets** | | |
| | | a) Current investment | - | - |
| | | b) Inventories | 3,322.53 | 3,154.24 |
| | | c) Trade receivables | 4,634.10 | 5,390.05 |
| | | d) Cash and bank balances | 945.36 | 238.60 |
| | | e) Short-term loans and advances | 5,400.26 | 624.25 |
| | | f) Other current assets | 1,731.99 | 494.98 |
| | | **Total current assets** | **16,034.24** | **9,902.12** |
| | | **Total assets** | **25,477.12** | **14,929.66** |

**For and on behalf of the Board of Directors of**
Dhansa Labs Limited
(Formely known as Ambey laboratories limited)

ARCHIT GUPTA

Digitally signed by ARCHIT GUPTA
Date: 2026.11.14 21:35:25 +05'30'

**Archit Gupta**
Whole Time Director
DIN: 00378409

Date: 14 November 2026
Place: Gurugram

**5 STANDALONE STATEMENT OF CASH FLOWS** *(All amounts in Rs. lacs, unless stated otherwise)*

| | | For the period ended | |
|---|---|---|---|
| | | **30.09.2026** | **30.09.2025** |
| **A.** | **Cash flow from operating activities** | | |
| | **Profit/(loss) before tax** | 427.14 | 300.56 |
| | **Adjustments for :** | | |
| | Depreciation and amortisation expense | 89.04 | 110.09 |
| | Interest expense and finance cost | 151.76 | 192.11 |
| | Interest income | (65.79) | (4.29) |
| | | **602.15** | **598.47** |
| | **Changes in assets and liabilities** | | |
| | (Increase) / Decrease in inventories | (168.29) | (69.92) |
| | (Increase) / Decrease in trade receivables | 755.95 | (954.49) |
| | (Increase) / Decrease in short term loans and advances | (4,776.01) | 87.75 |
| | (Increase) / Decrease in other assets | (1,254.08) | 31.75 |
| | Increase / (decrease) in trade payables | 1,695.18 | (124.59) |
| | Increase / (decrease) in other liabilities | 7,673.22 | (37.33) |
| | **Cash generated from operating activities** | **4,528.12** | **(468.35)** |
| | Taxes paid (net of refunds) | (9.52) | 1.37 |
| | **Net cash generated from operating activities** | **4,518.60** | **(466.98)** |
| **B.** | **Cash Flow from Investing Activities** | | |
| | (Purchase) Sale of Fixed Assets | (787.85) | (151.51) |
| | Investment in subsidiary companies | (920.00) | (10.00) |
| | Loan given | (2,765.89) | (363.28) |
| | Investment in Fixed Deposit | 3.37 | 1.79 |
| | Interest received | - | 4.29 |
| | **Net cash generated from/(used in) investing activities** | **(4,470.37)** | **(518.72)** |
| **C.** | **Cash flows from financing activities** | | |
| | Interest & Finance Cost | (150.56) | (192.11) |
| | Proceeds from issues of equity shares | 900.00 | - |
| | ( Repayments ) /proceeds of long term borrowings | 460.76 | 818.59 |
| | ( Repayments ) / proceeds of short term borrowings | (115.62) | (900.70) |
| | Proceeds from issues of share warrants | (436.03) | 1,250.03 |
| | **Net cash generated from/(used in) financing activities** | **658.54** | **975.81** |
| | **Net increase/(decrease) in cash and cash equivalents** | **706.77** | **(9.89)** |
| | Cash and cash equivalents at the beginning of year | 136.80 | 72.76 |
| | **Cash and cash equivalents at the end of year** | **843.57** | **62.87** |

The above statement of cash flow has been prepared under the 'Indirect Method'.

**6** The standalone financial results for the quarter ended 30 September 2026 represent balancing figures derived from the half-yearly results ended 30 September 2026 and the quarter ended 30 June 2026. Similarly, the figures for the quarter ended 30 September 2025 have been derived from the half-yearly results ended 30 September 2025 and the quarterly results ended 30 June 2025.

**7** During the year ended 31 March 2026, the company allotted 1,08,69,565 convertible equity warrants on preferential basis at an issue price of Rs. 46/- per warrant, aggregating to Rs. 4,999.99 lakhs, in accordance with Section 42 and Section 62(1)(c) of the Companies Act, 2013 and applicable provisions of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.

Against the said warrants, the company has received Rs. 2,161.54 lakhs up to 30 September 2026 towards warrant subscription/part consideration.

The money received against these warrants has been utilized for the purposes detailed in the table below.

(Rs. in lacs unless otherwise stated)

| **Object of issue** | **Total issue size** | **Amount received till 30 September 2026** | **Amount utilized till 30 September 2026** | **Amount unutilized as on 30 September 2026** | **Deviation (if any)** |
|---|---|---|---|---|---|
| The funds were utilised towards general corporate purposes, advances for plant and machinery, supporting ongoing capital expenditure; and land-related advances. | 4999.90 | 2161.54 | 2161.54 | - | N/A |
| **Total** | 4999.90 | 2161.54 | 2161.54 | - | N/A |

**8** The figures for the previous period have been regrouped / rearranged / reclassified wherever necessary.

**For and Behalf of Board of**
Dhansa Labs Limited
(Formerly known as Ambey Laboratories Limited)

ARCHIT GUPTA Digitally signed by ARCHIT GUPTA
Date: 2026.11.14 21:35:37 +05'30'

**Archit Gupta**
Whole Time Director
DIN: 00378409

Date: 14 November 2026
Place: Gurugram

KAPISH JAIN & ASSOCIATES
Chartered Accountants

117, 1st Floor, New Delhi House,
27, Barakhamba Road,
New Delhi – 110001
Tel: +91-11-40508780
Mob: +91 9711611551
Email: info@cakja.com

**Independent auditor's review report on consolidated un-audited financial results for the Quarter and Half year ended 30 September 2026 of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

**Review Report to**
**The Board of Directors**
**Dhansa Labs Limited**
(Formerly known as Ambey Laboratories Limited)

1. We have reviewed the accompanying Statement of Consolidated Un-audited Financial Results of **Dhansa Labs Limited** (Formerly known as Ambey Laboratories Limited) ("the Holding Company") and its two subsidiaries (together, the "Group") for the quarter and half year ended 30 September 2026 ("the Statement"). The Holding Company is submitting the Statement pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including relevant circulars issued by SEBI from time to time.

2. This statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been compiled from the related unaudited interim financial information which has been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard 25 "Interim Financial Reporting" (AS 25), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statements are free of material misstatements. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



4. The Statement includes the results of the following subsidiaries:

| S. No. | Name of the entity | Relation |
|---|---|---|
| 1 | Dhansa Green Energy Private Limited (w.e.f. August 14,2025) | Subsidiary Company |
| 2 | Dhansa Biofules Power Private Limited (w.e.f. January 27, 2026) | Subsidiary Company |

5. The accompanying Statement includes audited financial statements and other unaudited financial information in respect of 2 (two) subsidiaries, whose financial statements and other financial information reflect total assets of Rs. 3,140.13 Lakhs as at September 30, 2026, total revenues of Rs. 4.36 Lakhs, total net profit / (loss) after tax of Rs. (0.32) Lakhs for the half-year ended September 30, 2026 and total revenues of Rs. 4.36 Lakhs, total net profit / (loss) after tax of Rs. 0.16 Lakhs for the quarter ended September 30, 2026 and net cash (outflows) / inflows of Rs. 99.30 Lakhs for the half-year ended September 30, 2026. These financial statements and other financial information have been reviewed by their respective independent auditor.

   Our conclusion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of such auditors and the procedures performed by us are as stated in paragraph above.

   Our conclusion on the consolidated unaudited financial results is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditor.

6. Based on our review conducted as stated above, nothing has come to our attention that that causes us to believe that the accompanying statement, prepared in accordance with the generally accepted accounting principles in India ("GAAP") and in compliance with the applicable Accounting Standard as specified under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation, read with Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

7. During the year ended 31 March 2026, the holding company allotted 1,08,69,565 convertible equity warrants on preferential basis at an issue price of Rs. 46/- per warrant, aggregating to Rs. 4,999.99 lakhs, in accordance with Section 42 and Section 62(1)(c) of the Companies Act, 2013 and applicable provisions of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. Against the said warrants, the holding company has received Rs. 2,161.54 lakhs up to 30 September 2026 towards warrant subscription/part consideration.



The money received against these warrants has been utilized for the purposes detailed in the table below.

*(Rs. in lacs unless otherwise stated)*

| Object of issue | Total issue size | Amount received till September 30, 2026 | Amount utilized till September 30, 2026 | Amount unutilized as on September 30, 2026 | Deviation (if any) |
|---|---|---|---|---|---|
| The funds were utilized towards general corporate purposes, advances for plant and machinery, supporting ongoing capital expenditure; and land-related advances. | 4999.99 | 2161.54 | 2161.54 | - | N/A |

For **KAPISH JAIN & ASSOCIATES**
Chartered Accountants
Firm Registration No. 022743N




**CA Kapish Jain**
Partner
M. No.: 514162
UDIN: 26514162ZQSMDD3820
Place: New Delhi
Date: 14 November, 2026

**DHANSA LABS LIMITED**

**(Formerly known as Ambey Laboratories Limited)**

Regd. Office : Ground Floor,Property No.555 Tarla Mohalla,Ghitorni, South West Delhi, Delhi, India, 110030

Corp. Office : B18/9, Dlf Phase -1 Sector 26A, Gurugram-122002, Gurugram, Haryana, India, 122002

CIN: L74899DL1985PLC020490, Email:cs@ambeylab.com

**STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS**

**FOR THE QUARTER , HALF YEAR ENDED 30 SEPTEMBER 2026**

*(All amounts in Rs. lacs, unless stated otherwise)*

| Sl. No | Particulars | Querter ended | | | Half Year ended | | | Year ended |
|---|---|---|---|---|---|---|---|---|
| | | 30.09.2026 | 30.06.2026 | 30.09.2025 | 30.09.2026 | 31.03.2026 | 30.09.2025 | 31.03.2026 |
| | | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) |
| 1 | **Income** | | | | | | | |
| | a) Revenue from operations | 3,855.69 | 3,056.29 | 3,988.63 | 6,911.98 | 7,336.13 | 6,817.59 | 14,153.72 |
| | b) Other income | 0.55 | 3.27 | 11.32 | 3.82 | 117.59 | 13.37 | 130.96 |
| | **Total income** | **3,856.24** | **3,059.56** | **3,999.95** | **6,915.80** | **7,453.72** | **6,830.96** | **14,284.68** |
| 2 | **Expenses** | | | | | | | |
| | a) Cost of material consumed | 3,234.83 | 2,891.70 | 3,010.65 | 6,126.53 | 6,803.79 | 6,176.51 | 12,980.30 |
| | b) Changes in inventories of work-in-progress, finished goods | 122.26 | (194.07) | 506.07 | (71.81) | (113.23) | (226.46) | (339.69) |
| | c) Employee benefits expense | 41.15 | 30.32 | 46.63 | 71.47 | 38.77 | 77.01 | 115.78 |
| | d) Finance costs | 81.15 | 70.61 | 92.44 | 151.76 | 70.28 | 192.11 | 262.39 |
| | e) Depreciation and amortisation expense | 44.89 | 44.15 | 55.36 | 89.04 | 109.69 | 110.09 | 219.78 |
| | f) Other expenses | 123.21 | 64.18 | 122.34 | 187.39 | 105.21 | 201.28 | 306.49 |
| | **Total expenses** | **3,647.49** | **2,906.89** | **3,833.48** | **6,554.38** | **7,014.51** | **6,530.54** | **13,545.05** |
| 3 | **Profit/(loss) before exceptional item & tax (1-2)** | **208.75** | **152.67** | **166.47** | **361.42** | **439.21** | **300.42** | **739.63** |
| 4 | Exceptional Items | - | - | - | - | | - | - |
| 5 | **Profit/(loss) before tax (3-4)** | **208.75** | **152.67** | **166.47** | **361.42** | **439.21** | **300.42** | **739.63** |
| 6 | Tax expense | | | | | | | |
| | -Current tax | 29.19 | 59.16 | 34.16 | 88.35 | 70.44 | 56.52 | 192.11 |
| | -Deferred tax charge/ (benefit) | 10.94 | 20.92 | 24.22 | 31.86 | (43.14) | 38.40 | (4.74) |
| | -MAT credit entitlement | - | - | (34.16) | - | 121.67 | (56.52) | - |
| | **Tax expense** | **40.13** | **80.08** | **24.22** | **120.21** | **148.97** | **38.40** | **187.37** |
| 7 | **Net Profit/(Loss) after tax (5-6)** | **168.62** | **72.59** | **142.25** | **241.21** | **290.24** | **262.02** | **552.26** |
| 8 | **Paid-up Equity Share Captial (Face value of Rs.10/- each)** | 2,690.33 | 2,690.33 | 2,494.68 | 2,690.33 | 2,494.68 | 2,494.68 | 2,494.68 |
| 9 | Reserves (excluding revaluation reserve) | | | | | | | 4,642.61 |
| 10 | **Earnings per equity share** | | | | | | | |
| | **[Nominal value per share Rs. 10] (not annualised, except year end)** | | | | | | | |
| | Basic earnings per share (in ₹ ) | 0.64 | 0.28 | 0.57 | 0.91 | 1.16 | 1.05 | 2.21 |
| | Diluted earnings per share (in ₹ ) | 0.64 | 0.28 | 0.57 | 0.91 | 1.16 | 1.05 | 2.21 |

**Notes:-**

**1** The above Financial Results were reviewed by the Audit Committee and were thereafter approved by the Board of Directors at their meeting held on 14 November, 2026.

**2** The above results have been prepared in accordance with the recognition and measurement principles of Accounting Standard ("AS"), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

**3** The Holding company primarily engaged in the business of manufacturing and distribution of agro and home hygiene products. Hence, the Company has a single reportable segment as per the Accounting Standard - 17.

**For and on behalf of the Board of Directors of**
Dhansa Labs Limited
(Formely known as Ambey laboratories limited)

ARCHIT GUPTA Digitally signed by ARCHIT GUPTA
Date: 2026.11.14 21:35:56 +05'30'

**Archit Gupta**
Whole Time Director
DIN: 00378409

Date: 14 November 2026
Place: Gurugram

| 4 | | CONSOLIDATED STATEMENT OF ASSETS & LIABILITIES | *(All amounts in Rs. lacs, unless stated otherwise)* | |
|---|---|---|---|---|
| | | **Particulars** | **Consolidated** | |
| | | | **As at 30.09.2026** | **As at 31.03.2026** |
| | | **EQUITY AND LIABILITIES** | | |
| | 1 | **Shareholders' funds** | | |
| | | a) Share capital | 2,690.33 | 2,494.68 |
| | | b) Reserves and surplus | 6,638.15 | 5,692.61 |
| | | c) Money Received Against share warrant | 1,261.50 | 1,697.53 |
| | | **Total Equity** | **10,589.98** | **9,884.82** |
| | 2 | **Share Application Money Pending Allotment** | - | - |
| | 3 | **Liabilities** | | |
| | | **Non-current liabilities** | | |
| | | a) Long-Term Borrowings | 5,690.90 | 1,892.51 |
| | | b) Deferred tax liabilities | - | - |
| | | c) Other long-term liabilities | - | - |
| | | d) Long-term provisions | 41.90 | 41.88 |
| | | **Total non-current liabilities** | **5,732.80** | **1,934.39** |
| | | **Current liabilities** | | |
| | | a) Short-Term Borrowings | 1,958.93 | 2,074.55 |
| | | b) Trade payables | | |
| | | (i) Total outstanding dues of micro enterprises and | 122.11 | 68.26 |
| | | (ii) Total outstanding dues of creditors other than micro enterprises and small enterprises | 2,200.77 | 559.43 |
| | | c) Other current liabillities | 7,827.33 | 446.69 |
| | | d) Short-term provisions | 185.32 | 123.53 |
| | | **Total current liabilities** | **12,294.46** | **3,272.46** |
| | | **Total equity and liabilities** | **28,617.24** | **15,091.67** |
| | | **Assets** | | |
| | 1 | **Non-current assets** | | |
| | | a) Property, plant and equipment | | |
| | | (i) Property ,pant and equipment | 2,420.67 | 2,387.30 |
| | | (i) Intangible assets | 39.17 | 44.37 |
| | | (iii) Capital work-in-progress | 3,303.60 | 2,277.62 |
| | | b) Non-current investments | - | - |
| | | c) Deferred tax assets (Net) | 114.94 | 146.80 |
| | | d) Long-term loans and advances | 115.21 | 114.75 |
| | | **Total non-current assets** | **5,993.59** | **4,970.84** |
| | 2 | **Current assets** | | |
| | | a) Current investment | - | - |
| | | b) Inventories | 3,322.53 | 3,154.24 |
| | | c) Trade receivables | 4,634.10 | 5,390.05 |
| | | d) Cash and bank balances | 1,055.69 | 249.64 |
| | | e) Short-term loans and advances | 5,574.74 | 827.59 |
| | | f) Other current assets | 8,036.59 | 499.31 |
| | | **Total current assets** | **22,623.65** | **10,120.83** |
| | | **Total assets** | **28,617.24** | **15,091.67** |

**For and on behalf of the Board of Directors of**
Dhansa Labs Limited
(Formely known as Ambey laboratories limited)

ARCHIT GUPTA

Digitally signed by ARCHIT GUPTA
Date: 2026.11.14 21:36:12 +05'30'

**Archit Gupta**
Whole Time Director
DIN: 00378409

Date: 14 November 2026
Place: Gurugram

| 5 | | CONSOLIDATED STATEMENT OF CASH FLOWS | *(All amounts in Rs. lacs, unless stated otherwise)* | |
|---|---|---|---|---|
| | | | For the period ended | |
| | | | 30.09.2026 | 30.09.2025 |
| | A. | **Cash flow from operating activities** | | |
| | | **Profit/(loss) before tax** | 361.41 | 300.41 |
| | | **Adjustments for :** | | |
| | | Depreciation and amortisation expense | 89.04 | 110.09 |
| | | Interest expense and finance cost | 151.76 | 192.11 |
| | | Interest income | (3.37) | (4.29) |
| | | Consolidated adjustment | - | 7,492.97 |
| | | | **598.85** | **8,091.29** |
| | | **Changes in assets and liabilities** | | |
| | | (Increase) / Decrease in inventories | (168.29) | (3,061.23) |
| | | (Increase) / Decrease in trade receivables | 755.94 | (4,997.68) |
| | | (Increase) / Decrease in short term loans and advances | (4,747.08) | (1,154.40) |
| | | (Increase) / Decrease in other assets | (7,556.84) | (55.71) |
| | | Increase / (decrease) in trade payables | 1,695.18 | 538.50 |
| | | Increase / (decrease) in short term provisions | - | 34.54 |
| | | Increase / (decrease) in long term provisions | - | 53.59 |
| | | Increase / (decrease) in other liabilities | 7,379.43 | 156.76 |
| | | **Cash generated from operating activities** | **(2,042.81)** | **(394.33)** |
| | | Taxes paid (net of refunds) | (9.52) | (353.48) |
| | | **Net cash generated from operating activities** | **(2,052.33)** | **(747.82)** |
| | B. | **Cash Flow from Investing Activities** | | |
| | | (Purchase) Sale of Fixed Assets | (1,143.20) | (4,033.54) |
| | | Loan given | 2.04 | (119.02) |
| | | Investment in Fixed Deposit | - | (101.75) |
| | | Interest received | 3.37 | 4.29 |
| | | **Net cash generated from/(used in) investing activities** | **(1,137.80)** | **(4,250.02)** |
| | C. | **Cash flows from financing activities** | | |
| | | Interest & Finance Cost | (150.56) | (192.11) |
| | | Proceeds from issues of equity shares | 900.00 | - |
| | | ( Repayments ) /proceeds of long term borrowings | 3,798.39 | 1,895.02 |
| | | ( Repayments ) / proceeds of short term borrowings | (115.62) | 2,108.77 |
| | | Proceeds from issues of share warrants | (436.03) | 1,250.03 |
| | | **Net cash generated from/(used in) financing activities** | **3,996.19** | **5,061.71** |
| | | **Net increase/(decrease) in cash and cash equivalents** | **806.07** | **63.87** |
| | | Cash and cash equivalents at the beginning of year | 147.83 | - |
| | | **Cash and cash equivalents at the end of year** | **953.89** | **63.87** |

The above statement of cash flow has been prepared under the 'Indirect Method'.

**6** The consolidated financial results for the quarter ended 30 September 2026 were calculated by subtracting the consolidated results for the quarter ended 30 June 2026 from the consolidated results for the half year ended 30 September 2026. For the comparative quarter ended 30 September 2025, the Company subtracted its standalone results for the quarter ended 30 June 2025 from the consolidated results for the half year ended 30 September 2025. The Company used standalone results for the June 2025 quarter because it had no subsidiaries during that quarter.

**7** During the year ended 31 March 2026, the Holding Company allotted 1,08,69,565 convertible equity warrants on preferential basis at an issue price of Rs. 46/- per warrant, aggregating to Rs. 4,999.99 lakhs, in accordance with Section 42 and Section 62(1)(c) of the Companies Act, 2013 and applicable provisions of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.

Against the said warrants, the Holding Company has received Rs. 2,161.54 lakhs up to 30 September 2026 towards warrant subscription/part consideration.

The money received against these warrants has been utilized for the purposes detailed in the table below.

*( Rs. in lacs unless otherwise stated)*

| Object of issue | Total issue size | Amount received till 30 September 2026 | Amount utilized till 30 September 2026 | Amount unutilized as on 30 September 2026 | Deviation (if any) |
|---|---|---|---|---|---|
| The funds were utilised towards general corporate purposes, advances for plant and machinery, supporting ongoing capital expenditure; and land-related advances. | 4999.99 | 2161.54 | 2161.54 | - | N/A |
| **Total** | 4999.99 | 2161.54 | 2161.54 | - | N/A |

**8** The Consolidated financial results for the quarter, half-year and year ended on 30 September 2026 includes the following entities of the Group :

| S.no. | Name of the entity | Relation |
|---|---|---|
| 1 | Dhansa Green Energy Private Limited (w.e.f. 14 August 2025) | Subsidiary Company |
| 2 | Dhansa Biofules Power Private Limited (w.e.f. 27 January 2026) | Subsidiary Company |

**9** The figures for the previous period have been regrouped / rearranged / reclassified wherever necessary.

**For and Behalf of Board of**
Dhansa Labs Limited
(Formerly known as Ambey Laboratories Limited)

ARCHIT GUPTA

Digitally signed by ARCHIT GUPTA
Date: 2026.11.14 21:36:26 +05'30'

**Archit Gupta**
Whole Time Director
DIN: 00378409

Date: 14 November 2026
Place: Gurugram

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

| | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | | | | | | | | | | | | | | Details need to be provided only if any of the transactions / applicable transactions with the related party is a loan, inter-corporate deposit, advance or investment which is beyond the limits set by the Board of Directors. The details should be given with respect to such loan / advance / investment. | | | | | | | | |
| Sr. No. | Details of the party (listed entity or its subsidiary) entering into the transaction | | Details of the counterparty | | | | | | | | | | Value of transaction during the reporting period | In case monies are due to either party as a result of the transaction | | In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments | | | | Details of the loans, inter-corporate deposits, advances or investments | | | | | | | | |
| | Name | PAN | Name | PAN | Relationship of the counterparty with the listed entity or its subsidiary | Type of related party transaction | Details of other related party transaction | Value of the related party transaction as approved by the audit committee | Previous transactions with the same related party during the financial year | Value of the related party transaction as approved by the audit committee | Date of Audit Committee Meeting where the related party transaction was approved | Value of the transaction during the reporting period | Opening balance | Closing balance | Nature of indebtedness; cost of funds or tenure | Details of the indebtedness | Cost | Tenure | Nature (loan / advance / inter-corporate deposit / investment) | Interest Rate (%) | Tenure | Secured / unsecured | Purpose for which the funds will be utilised by the ultimate recipient of funds (end-usage) | Note | | | | |
| Add | Delete | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 1 | Dhanuka Labs | AAACD1111F | Gamaka Finance Private Limited | AAACG4567G | Common Directors, one shareholder, between both the parties. | Sale of goods or services | | 75,000.00 | No | 0.00 | 01-03-2024 | 9,631 | 748.91 | 0.00 | | | | | | | | | | | | | |
| 2 | Dhanuka Labs | AAACD1111F | Gamaka Finance Private Limited | AAACG4567G | Common Directors, one shareholder, between both the parties. | Purchase of goods or services | | 40,000.00 | No | 0.00 | 01-03-2024 | 417.19 | 0.00 | 2,700.47 | | | | | | | | | | | | | |
| 3 | Dhanuka Labs | AAACD1111F | Dhanuka Commercials Private Limited | AAACD6677B | Common Directors, one shareholder, between both the parties. | Sale of goods or services | | 180,000.00 | No | 0.00 | 01-04-2024 | 24,000 | 179.00 | 756.75 | | | | | | | | | | | | | |
| 4 | Dhanuka Labs | AAACD1111F | Anil Dhanuka | AHPD1461E | KMP & Promoter | Remuneration | | 7,200 | No | 0.00 | 01-04-2024 | 1,200 | 0.00 | 0.00 | | | | | | | | | | | | | |
| 5 | Dhanuka Labs | AAACD1111F | Gopi Gupta | AHRPG7149F | Director and Promoter | Director's remuneration | Salary for one month's period | 7,200 | No | 0.00 | 01-04-2024 | 4.75 | 44.75 | 0.00 | | | | | | | | | | | | | |
| 6 | Dhanuka Labs | AAACD1111F | Vinod Kumar | BDKPK3994P | KMP & CEO | Remuneration | | 12.40 | No | 0.00 | 01-04-2024 | 2.00 | 0.00 | 1.20 | | | | | | | | | | | | | |
| 7 | Dhanuka Labs | AAACD1111F | Manisha Dhanuka | AHLPM4144B | KMP & CS | Remuneration | | 9.00 | No | 0.00 | 01-04-2024 | 1.50 | 0.50 | 0.00 | | | | | | | | | | | | | |
| 8 | Dhanuka Labs | AAACD1111F | Rishi Dhanuka | BNDPD3138F | Independent Director | Director's remuneration | Director's fees for the meeting attended | 0.80 | No | 0.00 | 01-04-2024 | 0.80 | 0.00 | 0.00 | | | | | | | | | | | | | |
| 9 | Dhanuka Labs | AAACD1111F | Arun Dhanuka | AAEPD2153L | Independent Director | Director's remuneration | Director's fees for the meeting attended | 0.80 | No | 0.00 | 01-04-2024 | 0.80 | 0.00 | 0.00 | | | | | | | | | | | | | |
| 10 | Dhanuka Labs | AAACD1111F | Bhavik Gadhiya | EJXPG4725L | Independent Director | Director's remuneration | Sitting fees for one month's period | 0.80 | No | 0.00 | 01-04-2024 | 0.40 | 0.00 | 0.00 | | | | | | | | | | | | | |
| Total value of transactions during the reporting period | | | | | | | | | | | | | 355.53 | | | | | | | | | | | | | | |

Note: